A survey of treatment practice for patients with neuromyelitis optica spectrum disorder under satralizumab treatment using Japanese claims database

A survey of treatment practice for patients with neuromyelitis optica spectrum disorder under satralizumab treatment using Japanese claims database - A survey of treatment practice for patients with NMOSD under satralizumab treatment using Japanese claims database

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049131

Enrollment

Registered

2022-10-07

Start date

2022-10-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuromyelitis optica spectrum disorder (NMOSD)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were diagnosed as NMOSD and prescribed satralizumab at least once by March 2022 with more than 90 days of claim record prior to prescription of satralizumab

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
Proportion of patients who reduced oral corticosteroid to 0 mg at day 360 without relapse under continuous satralizumab prescription	—

Countries

Japan

Contacts

Public ContactNobuo Nishijima

CHUGAI PHARMACEUTICAL CO.,LTD. Medical Affairs Div.

cma-clinicaltrial@chugai-pharm.co.jp03-3273-0866

Outcome results